Algorae Receives A$318,771 R&D Cash Rebate from ATO
Filed with ASX · · 1 page · English
Summary by 6ix AI
The funds will be strategically used to advance Algorae's artificial intelligence-driven drug discovery programs and support early revenue opportunities. This announcement highlights Algorae's commitment to leveraging AI for pharmaceutical innovation and the development of novel drug candidates.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Algorae Pharmaceuticals Limited on 6ix
Story so far
Earlier from Algorae Pharmaceuticals
- Peter Mac Partners with Algorae on AI Drug Targets
- Algorae Receives A$451,359 R&D Cash Rebate from ATO
- Half Yearly Report Announcement and Appendix 4D
- Significant Cardioprotection Qualities in AI-168 Studies
- 24 New AI-Generated Drug Targets
Later from Algorae Pharmaceuticals
- Annual Report and Appendix 4E
- Algorae Signs Exclusive License Agreement with Sakar
- Algorae Signs Binding Term Sheet with Cadila Pharmaceuticals
- AlgoraeOS Version 2 AI Platform Launched
- Prospectus - Loyalty Options Offer
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals